Thermo Fisher Scientific Inc. $TMO Position Boosted by ARQ Wealth Advisors LLC

Key Points

• ARQ Wealth Advisors LLC boosted its Thermo Fisher Scientific stake by 461.6% in the first quarter, ending with 4,173 shares valued at about $2.05 million.
• Thermo Fisher reported better-than-expected Q1 results, with EPS of $5.44 versus estimates of $5.25 and revenue of $11.01 billion, up 6.2% from a year earlier.
• The company announced a quarterly dividend of $0.47 per share and saw mixed analyst sentiment, with a consensus rating of Moderate Buy and an average price target of $602.14.

ARQ Wealth Advisors LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 461.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,173 shares of the medical research company's stock after acquiring an additional 3,430 shares during the quarter. ARQ Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $2,051,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. J. Stern & Co. LLP grew its holdings in shares of Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares during the last quarter. Norges Bank acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $3,072,744,000. Auto Owners Insurance Co grew its position in Thermo Fisher Scientific by 57,845.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company's stock worth $1,406,844,000 after purchasing an additional 2,423,706 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Thermo Fisher Scientific by 2,183.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company's stock valued at $770,000,000 after purchasing an additional 1,270,643 shares during the period. Finally, Wellington Management Group LLP raised its holdings in shares of Thermo Fisher Scientific by 88.9% during the third quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company's stock valued at $1,309,292,000 after buying an additional 1,270,191 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.4%

Thermo Fisher Scientific stock traded up $2.01 during midday trading on Friday, reaching $526.72. The stock had a trading volume of 1,233,008 shares, compared to its average volume of 1,993,707. The firm's fifty day simple moving average is $478.23 and its two-hundred day simple moving average is $516.44. The firm has a market cap of $195.74 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 2.33 and a beta of 0.87. Thermo Fisher Scientific Inc. has a twelve month low of $403.36 and a twelve month high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective for the company. HSBC cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating and decreased their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Royal Bank Of Canada set a $490.00 price objective on shares of Thermo Fisher Scientific and gave the company a "sector perform" rating in a research note on Thursday, May 14th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price on the stock. Finally, Morgan Stanley restated an "overweight" rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $602.14.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.